Analysts think CATX stock price could increase by 646%
Apr 03, 2025, 11:25 AM
24.63%
What does CATX do
Perspective Therapeutics, based in Seattle, is a biotechnology company focused on developing radiopharmaceuticals for cancer treatment using the alpha-emitting isotope 212Pb. Their programs for melanoma and neuroendocrine tumors are in Phase I/IIa trials.
15 analysts think CATX stock price will increase by 646.34%. The current median analyst target is $15.30 compared to a current stock price of $2.05. The lowest analysts target is $6.06 and the highest analyst target is $22.05.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
